Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zydus gets FDA ok for bromocriptine mesylate

This article was originally published in Scrip

Executive Summary

Zydus Cadilahas received US FDAapproval to market bromocriptine mesylate capsules 5mg, a generic version of Novartis's Parlodel capsules. Bromocriptine mesylate capsules are used for the treatment of hyperprolactinaemia-associated dysfunctions, acromegaly, and Parkinson's disease. Sales of bromocriptine mesylate capsules were estimated at $11.4 million in 2007. Zydus now has 40 ANDA approvals and has filed 79 ANDAs with the FDA.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC003299

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel